NASDAQ$RCKT
Rocket Pharmaceuticals Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Rocket Pharmaceuticals reported financial results for Q2 2024 and provided updates on its pipeline and regulatory progress.
Rocket Pharmaceuticals reported its Q2 2024 financial results, highlighting the advancement of its clinical pipeline, including RP-A501 and RP-A601 cardiac programs, and progress towards FDA approval for KRESLADI. The company's cash, cash equivalents, and investments totaled $278.8 million, expected to fund operations into 2026.
- Continued advancement of Phase 2 pivotal study of RP-A501 for Danon Disease with ongoing patient enrollment.
- Received orphan medicinal product designation from the European Commission for RP-A601 for PKP2 arrhythmogenic cardiomyopathy (ACM).
- FDA review of limited additional Chemistry Manufacturing and Controls (CMC) information underway for KRESLADITM for the treatment of severe leukocyte adhesion deficiency-I (LAD-I).
- Progressed Fanconi Anemia (FA) and Pyruvate Kinase Deficiency (PKD) programs through regulatory and clinical milestones.
Headline financials
Revenue & EPS history
Rocket · Revenue · Quarterly
$0
Forward guidance
Rocket Pharmaceuticals expects its cash, cash equivalents and investments of $278.8 million as of June 30, 2024, will be sufficient to fund its operations into 2026.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+0.8%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-1.9%
Avg return
30 days after
51%
23 / 45 earnings
Positive
+18.2%
Q1 2023
Best reaction
-17.7%
Q1 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.4% | -6.0% | -29.0% | |
| Q4 2025 | +10.8% | +6.4% | -16.8% | |
| Q3 2025 | +0.3% | +2.2% | +2.8% | |
| Q1 2025 | -0.6% | +0.9% | -55.7% | |
| Q4 2024 | +0.5% | -2.0% | -19.3% | |
| Q3 2024 | -0.7% | -8.8% | -21.0% | |
| Q2 2024 | -3.6% | -8.8% | -14.5% | |
| Q1 2024 | -0.5% | -3.2% | -1.6% | |
| Q4 2023 | +5.0% | +4.3% | -6.9% | |
| Q3 2023 | -2.4% | -11.6% | +23.1% | |
| Q2 2023 | -2.6% | -4.2% | -7.8% | |
| Q1 2023 | +18.2% | +16.4% | +23.0% | |
| Q4 2022 | +5.9% | +14.8% | -7.7% | |
| Q3 2022 | -6.0% | -10.8% | +9.9% | |
| Q2 2022 | +4.3% | +12.3% | +1.5% | |
| Q1 2022 | -15.2% | -17.2% | +20.4% | |
| Q4 2021 | +4.3% | -2.6% | -11.4% | |
| Q3 2021 | +10.3% | +8.0% | -30.2% | |
| Q2 2021 | -4.9% | -13.9% | -1.8% | |
| Q1 2021 | -3.9% | -6.5% | +3.6% | |
| Q4 2020 | -0.7% | -1.8% | -16.9% | |
| Q3 2020 | +5.3% | +0.2% | +9.2% | |
| Q2 2020 | +6.3% | +10.6% | -8.1% | |
| Q1 2020 | -1.5% | +12.7% | +8.5% | |
| Q4 2019 | -1.1% | -7.7% | -30.3% | |
| Q3 2019 | +10.2% | +4.0% | +50.6% | |
| Q2 2019 | +4.5% | -3.2% | +0.4% | |
| Q1 2019 | +1.6% | -8.7% | -14.6% | |
| Q4 2018 | -4.7% | -2.1% | +27.4% | |
| Q3 2018 | -1.0% | -12.5% | -17.6% | |
| Q2 2018 | +3.8% | -5.3% | +9.0% | |
| Q1 2018 | +6.5% | +19.8% | +23.2% | |
| Q4 2017 | -0.4% | +0.2% | -19.2% | |
| Q3 2017 | +2.0% | +15.7% | +3.6% | |
| Q2 2017 | +8.3% | +16.7% | +13.3% | |
| Q1 2017 | -9.6% | +0.0% | -1.4% | |
| Q4 2016 | +8.7% | -4.3% | +24.6% | |
| Q3 2016 | +4.5% | +4.5% | +1.5% | |
| Q2 2016 | +0.1% | +2.7% | +1.8% | |
| Q1 2016 | -17.7% | — | — | |
| Q4 2015 | -3.3% | — | — | |
| Q3 2015 | -6.9% | — | — | |
| Q2 2015 | -4.1% | — | — | |
| Q1 2015 | +0.3% | — | — | |
| Q4 2014 | +7.9% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro